A Study to Assess the Effectiveness, Safety, and Pharmacokinetics of TMC435 in Combination With Peginterferon Alfa-2a and Ribavirin in Hepatitis-C Infected Patients (DRAGON)
A Phase II, Randomized, Open-label Study in Japan to Investigate the Efficacy, Safety and Pharmacokinetics of TMC435 as Part of a Treatment Regimen Including Peginterferon Alfa-2a and Ribavirin in Treatment naïve, Genotype 1, Chronic Hepatitis C Subjects
Sponsor: Janssen Pharmaceutical K.K.
Listed as NCT00996476, this PHASE2 trial focuses on Hepatitis C, Chronic and remains completed. Sponsored by Janssen Pharmaceutical K.K., it has been updated 8 times since 2009, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE2
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Jul 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Janssen Pharmaceutical K.K.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Amagasaki, Japan , Hiroshima, Japan , Kagoshima, Japan , Kawasaki, Japan , Kitakyushu, Japan , Kurume, Japan , Kyoto, Japan , Matsumoto, Japan , Musashino, Japan , Nishinomiya, Japan and 9 more locations